Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma

Biothera announced today that it has acquired the anti-cancer monoclonal antibody AS1402 from Antisoma for undisclosed terms.

10 Mar 2011

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

Pepscan Therapeutics, the Dutch biotechnology firm focusing on protein mimicry technology, today announces that it has signed a Research and License Agreement with Crucell Holland B.V. the Dutch developer of vaccines and antibodies.

10 Mar 2011

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

10 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

USPTO grants new patent to Intellect's Alzheimer's vaccine

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a new patent from the United States Patent and Trademark Office in relation to the Company's RECALL-VAXTM technology platform.

9 Mar 2011

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Patrys Limited (ASX: PAB), which is developing a new class of antibody molecules for the treatment of cancer, is pleased to announce success in obtaining commercial production yields for natural human antibody PAT-SC1, facilitating the advancement of this promising product toward a second human clinical trial for the treatment of cancer.

8 Mar 2011

Neoprobe reports positive feedback from FDA for RIGScan development

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has completed a successful pre-IND meeting with the U.S. Food and Drug Administration on the development of RIGScan CR, the Company's proprietary radiopharmaceutical for the detection of colorectal cancer tumors.

8 Mar 2011

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.

7 Mar 2011

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.

7 Mar 2011

IMMY, University of Nevada, Reno collaborate to make new blood test for Cryptococcosis

A new, rapid blood test that could lead to early diagnosis and potentially save the lives of hundreds of thousands of people stricken with fungal meningitis, a leading cause of AIDS-related deaths in developing countries, is getting closer to market with a recent collaboration between the University of Nevada, Reno and Immuno-Mycologics in Oklahoma.

5 Mar 2011

Eisai receives FDA approval for BANZEL Oral Suspension to treat seizures linked with LGS

Eisai Inc. today announced that the U.S. Food and Drug Administration has approved BANZEL Oral Suspension, 40 mg/mL, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.

3 Mar 2011

Scientists uncover genetic pathway that affects breast cancer development

Using recent advances in genomics, researchers have uncovered a genetic pathway that affects the development of breast cancer, work that could help predict which patients are at risk of relapse for the disease.

3 Mar 2011

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Eisai announced today that results from the global Phase III clinical study "EMBRACE" will be published online in The Lancet.

3 Mar 2011

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

Vical Incorporated announced today the receipt of Scientific Advice from the European Medicines Agency (EMA) recommending practical efficacy endpoints for a Phase 3 trial of the company's TransVax™ therapeutic cytomegalovirus (CMV) vaccine.

3 Mar 2011

U-M scientists identify potential target to treat aggressive prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have identified a potential target to treat an aggressive type of prostate cancer. The target, a gene called SPINK1, could be to prostate cancer what HER2 has become for breast cancer.

3 Mar 2011

IAVI, THSTI collaborate to establish HIV Vaccine Design Program in India

The Translational Health Sciences and Technology Institute, an autonomous institute of the Indian government's Department of Biotechnology, and the International AIDS Vaccine Initiative announced today an agreement to jointly establish, operate and fund an HIV Vaccine Design Program in India.

2 Mar 2011

Calypte Biomedical completes new Aware HIV-1/2 oral fluid rapid test internal studies

Calypte Biomedical Corporation, a developer, manufacturer and marketer of HIV diagnostic tests, today announced successful completion of internal studies of its new Aware HIV-1/2 oral fluid rapid test for the US and international markets.

2 Mar 2011

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma patients.

1 Mar 2011

EPO cancels PDL's '216B European Patent

PDL BioPharma, Inc. announced today that the Technical Board of Appeal of the European Patent Office has cancelled its hearing in which three appellants sought to have a 2007 decision upholding PDL's European Patent No. 0 451 216B overturned and the patent revoked.

1 Mar 2011

New research reveals how maternal antibodies block immune response to measles virus

New research that reveals how maternal antibodies block an immune response to the measles virus is a first step toward improving current childhood vaccination practices, scientists say.

1 Mar 2011

Antibody News and Research

Further Reading

Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

USPTO grants new patent to Intellect's Alzheimer's vaccine

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Neoprobe reports positive feedback from FDA for RIGScan development

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

IMMY, University of Nevada, Reno collaborate to make new blood test for Cryptococcosis

Eisai receives FDA approval for BANZEL Oral Suspension to treat seizures linked with LGS

Scientists uncover genetic pathway that affects breast cancer development

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

U-M scientists identify potential target to treat aggressive prostate cancer

IAVI, THSTI collaborate to establish HIV Vaccine Design Program in India

Calypte Biomedical completes new Aware HIV-1/2 oral fluid rapid test internal studies

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

EPO cancels PDL's '216B European Patent

New research reveals how maternal antibodies block immune response to measles virus

Event guide: 5th Novel Conjugates Summit 2026 eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo